TY  - JOUR
A1  - Kessler, Michael
A1  - Hertel, Dietrich
A1  - Jungkunst, Hermann F.
A1  - Kluge, Jürgen
A1  - Abrahamczyk, Stefan
A1  - Bos, Merijn
A1  - Buchori, Damayanti
A1  - Gerold, Gerhard
A1  - Gradstein, S. Robbert
A1  - Köhler, Stefan
A1  - Leuschner, Christoph
A1  - Moser, Gerald
A1  - Pitopang, Ramadhanil
A1  - Saleh, Shahabuddin
A1  - Schulze, Christian H.
A1  - Sporn, Simone G.
A1  - Steffan-Dewenter, Ingolf
A1  - Tjitrosoedirdjo, Sri S.
A1  - Tscharntke, Teja
T1  - Can Joint Carbon and Biodiversity Management in Tropical Agroforestry Landscapes Be Optimized?
JF  - PLoS One
N2  - Managing ecosystems for carbon storage may also benefit biodiversity conservation, but such a potential 'win-win' scenario has not yet been assessed for tropical agroforestry landscapes. We measured above-and below-ground carbon stocks as well as the species richness of four groups of plants and eight of animals on 14 representative plots in Sulawesi, Indonesia, ranging from natural rainforest to cacao agroforests that have replaced former natural forest. The conversion of natural forests with carbon stocks of 227-362 Mg C ha\(^{-1}\) to agroforests with 82-211 Mg C ha\(^{-1}\) showed no relationships to overall biodiversity but led to a significant loss of forest-related species richness. We conclude that the conservation of the forest-related biodiversity, and to a lesser degree of carbon stocks, mainly depends on the preservation of natural forest habitats. In the three most carbon-rich agroforestry systems, carbon stocks were about 60% of those of natural forest, suggesting that 1.6 ha of optimally managed agroforest can contribute to the conservation of carbon stocks as much as 1 ha of natural forest. However, agroforestry systems had comparatively low biodiversity, and we found no evidence for a tight link between carbon storage and biodiversity. Yet, potential win-win agroforestry management solutions include combining high shade-tree quality which favours biodiversity with cacao-yield adapted shade levels.
KW  - forest soils
KW  - stocks
KW  - diversity
KW  - sequestration
KW  - conversion
KW  - balance
KW  - root
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-132016
VL  - 7
IS  - 10
ER  - 
TY  - JOUR
A1  - Hecht, Markus
A1  - Meier, Friedegund
A1  - Zimmer, Lisa
A1  - Polat, Bülent
A1  - Loquai, Carmen
A1  - Weishaupt, Carsten
A1  - Forschner, Andrea
A1  - Gutzmer, Ralf
A1  - Utikal, Jochen S.
A1  - Goldinger, Simone M.
A1  - Geier, Michael
A1  - Hassel, Jessica C.
A1  - Balermpas, Panagiotis
A1  - Kiecker, Felix
A1  - Rauschenberg, Ricarda
A1  - Dietrich, Ursula
A1  - Clemens, Patrick
A1  - Berking, Carola
A1  - Grabenbauer, Gerhard
A1  - Schadendorf, Dirk
A1  - Grabbe, Stephan
A1  - Schuler, Gerold
A1  - Fietkau, Rainer
A1  - Distel, Luitpold V.
A1  - Heinzerling, Lucie
T1  - Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
JF  - British Journal of Cancer
N2  - Background:
Concomitant radiation with BRAF inhibitor (BRAFi) therapy may increase radiation-induced side effects but also potentially improve tumour control in melanoma patients.

Methods:
A total of 155 patients with BRAF-mutated melanoma from 17 European skin cancer centres were retrospectively analysed. Out of these, 87 patients received concomitant radiotherapy and BRAFi (59 vemurafenib, 28 dabrafenib), while in 68 patients BRAFi therapy was interrupted during radiation (51 vemurafenib, 17 dabrafenib). Overall survival was calculated from the first radiation (OSRT) and from start of BRAFi therapy (OSBRAFi).

Results:
The median duration of BRAFi treatment interruption prior to radiotherapy was 4 days and lasted for 17 days. Median OSRT and OSBRAFi in the entire cohort were 9.8 and 12.6 months in the interrupted group and 7.3 and 11.5 months in the concomitant group (P=0.075/P=0.217), respectively. Interrupted vemurafenib treatment with a median OSRT and OSBRAFi of 10.1 and 13.1 months, respectively, was superior to concomitant vemurafenib treatment with a median OSRT and OSBRAFi of 6.6 and 10.9 months (P=0.004/P=0.067). Interrupted dabrafenib treatment with a median OSRT and OSBRAFi of 7.7 and 9.8 months, respectively, did not differ from concomitant dabrafenib treatment with a median OSRT and OSBRAFi of 9.9 and 11.6 months (P=0.132/P=0.404). Median local control of the irradiated area did not differ in the interrupted and concomitant BRAFi treatment groups (P=0.619). Skin toxicity of grade ≥2 (CTCAE) was significantly increased in patients with concomitant vemurafenib compared to the group with treatment interruption (P=0.002).

Conclusions:
Interruption of vemurafenib treatment during radiation was associated with better survival and less toxicity compared to concomitant treatment. Due to lower number of patients, the relevance of treatment interruption in dabrafenib treated patients should be further investigated. The results of this analysis indicate that treatment with the BRAFi vemurafenib should be interrupted during radiotherapy. Prospective studies are desperately needed.
KW  - radiation
KW  - radiotherapy
KW  - BRAF
KW  - vemurafenib
KW  - dabrafenib
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-227970
VL  - 118
ER  -